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Abstract
Background: The relative efficacy of antiemetics for the treatment of postoperative nausea and
vomiting (PONV) is poorly understood.
Methods: Systematic search (MEDLINE, Embase, Cochrane Library, bibliographies, any language,
to 8.2000) for randomised comparisons of antiemetics with any comparator for the treatment of
established PONV. Dichotomous data on prevention of further nausea and vomiting, and on side
effects were combined using a fixed effect model.
Results: In seven trials (1,267 patients), 11 different antiemetics were tested without placebos;
these data were not further analysed. Eighteen trials (3,809) had placebo controls. Dolasetron
12.5–100 mg, granisetron 0.1–3 mg, tropisetron 0.5–5 mg, and ondansetron 1–8 mg prevented
further vomiting with little evidence of dose-responsiveness; with all regimens, absolute risk
reductions compared with placebo were 20%–30%. The anti-nausea effect was less pronounced.
Headache was dose-dependent. Results on propofol were contradictory. The NK1 antagonist
GR205171, isopropyl alcohol vapor, metoclopramide, domperidone, and midazolam were tested
in one trial each with a limited number of patients.
Conclusions: Of 100 vomiting surgical patients receiving a 5-HT3 receptor antagonist, 20 to 30
will stop vomiting who would not have done so had they received a placebo; less will profit from
the anti-nausea effect. There is a lack of evidence for a clinically relevant dose-response; minimal
effective doses may be used. There is a discrepancy between the plethora of trials on prevention
of PONV and the paucity of trials on treatment of established symptoms. Valid data on the
therapeutic efficacy of classic antiemetics, which have been used for decades, are needed.
Introduction
Postoperative nausea and vomiting (PONV) are among
the most common adverse events after surgery and an-
aesthesia. Compared with other postoperative complica-
tions (for instance, wound infection, deep vein
thrombosis or myocardial ischemia), PONV is of minor
medical importance; it almost never kills, and it never
becomes chronic. However, PONV may be very distress-
ing for patients. Workload for nursing staff dealing with
vomiting patients is increased. In ambulatory surgery,
intractable PONV may lead to unanticipated hospital ad-
mission.
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In France, 10% percent of the population underwent an
anaesthetic procedure in 1996 [1]. On average 30% of pa-
tients are suffering from PONV symptoms [2], and 1% of
surgical outpatients need to be admitted to hospital due
to intractable PONV [3–5]. Extrapolating these numbers
to the UK suggests that every year almost 2'000'000 peo-
ple suffer from PONV symptoms, and about 20'000 out-
patients need to be admitted following ambulatory
surgery due to intractable PONV. Thus, PONV is likely to
create considerable extra costs for health care systems.
Much research on the control of PONV has been con-
ducted during the last four decades. The majority of clin-
ical trials focuses on prophylaxis of PONV (i.e. patients
receive an antiemetic at induction of anaesthesia, during
surgery or shortly before they wake up). There are, how-
ever, several problems with the prevention of PONV.
First, the efficacy of prophylactic antiemetic interven-
tions in the daily surgical setting (i.e. when the baseline
risk for PONV is not particularly high) is often disap-
pointing [2]. Second, there is no evidence that prophy-
laxis decreases the likelihood of unanticipated admission
[2]. Third, prophylaxis of PONV is likely to be less cost-
effective than treatment of established symptoms [6].
And finally, with prevention strategies, patients who ac-
tually do not need any prophylaxis are unnecessarily ex-
posed to a drug, and are thus put at risk of suffering from
unnecessary adverse drug reactions.
Efficacious and safe treatment strategies for patients
who are nauseated or who are vomiting after surgery are
needed. The aim of this study was to systematically re-
view the literature on valid data on any treatment of es-
tablished PONV symptoms, to critically appraise the
data, to test for dose-responsiveness for each drug, and
to estimate relative efficacy and likelihood for harm of
the various treatments.
Methods
Systematic search
We searched the MEDLINE (PubMed, from 1966), and
EMBASE (from 1974) databases using different search
strategies. We also searched the Cochrane Controlled
Trials Register (Cochrane Library 2000, issue IV). We
used the free text terms (postoperative OR postopera-
tive OR postsurg*), (nausea OR vomiting OR emesis OR
retching), (randomised OR randomized), (treatment),
NOT (chemotherapy OR radiotherapy), NOT (preven-
tion OR prophylaxis) and combinations of these terms.
The date of the last electronic search was 21.8.2000. We
checked reference lists of retrieved reports and relevant
review articles, and we searched our own comprehensive
in-house bibliography. Authors of original trials were
contacted when there was ambiguity about the data. We
did not contact manufacturers.
Inclusion and exclusion criteria, validity assessment, data 
extraction
We included full reports of randomised comparisons of
any therapeutic antiemetic intervention (experimental
intervention) with placebo, no treatment or another an-
tiemetic (control intervention) in vomiting or nauseated
postoperative patients. When Intralipid® was used as a
control in propofol trials (to maintain blinding due to its
milky-white colour), it was considered as an inactive
control.
Retrieved reports were screened by one author (FK). Re-
ports, which did not clearly meet inclusion criteria were
excluded at this stage. All potentially relevant reports
were then read by all authors independently who scored
them for methodological validity using the three-item,
five point Oxford scale taking into account randomisa-
tion, double-blinding, and description of withdrawals
[7]. The minimum validity requirement for an included
trial was an adequate method of randomisation (for in-
stance, a table of random numbers). Trials with pseudo-
randomisation (for instance, according to patients' date
of birth) were excluded.
The main endpoint of efficacy was a "success" (i.e. no fur-
ther nausea or vomiting in a nauseated or vomiting pa-
tient). According to previous analyses [8], and in
agreement with the majority of all retrieved trials, we
distinguished between two arbitrarily defined observa-
tions periods: "early success" was within or close to 6
hours after administration of the study drugs, and "late
success" was within or close to 24 hours. Dichotomous
data on anti-vomiting and anti-nausea efficacy were sep-
arately extracted, and separately analysed. When no dis-
tinction was made between nausea and vomiting, the
data were not further analysed. Data on adverse drug re-
actions were analysed when they were reported in di-
chotomous form. Data on patients' satisfaction, duration
of hospital stay, number of vomiting episodes, degree of
nausea, or number of rescue treatments were not ana-
lysed since these data were inconsistently reported.
Sponsorship was assumed when it was acknowledged in
the original paper or when a representative of the manu-
facturer was a co-author of the paper. All data were ex-
tracted by one author (FK) and then checked by the two
others independently. Authors met to agree consensus
on validity scores and extracted data; discrepancies were
resolved by discussion.
Analyses
For both efficacy and harm we calculated relative risks
with 95% confidence intervals [9]. A statistically signifi-
cant difference between an experimental intervention
and control was assumed when the 95% confidence in-
terval around the relative risk did not include 1. DataBMC Anesthesiology 2001, 1:2 http://www.biomedcentral.com/1471-2253/1/2
from independent trials were combined only when the
data represented clinically homogenous subgroups. Such
subgroups would include comparisons of data of the
same dose and route of administration of the same ex-
perimental intervention, with the same control interven-
tion (for instance, a placebo), and reporting on the same
emesis endpoint (for instance vomiting) during the same
observation period (for instance late success). A fixed ef-
fect model was used to combine these clinically homoge-
nous data [10].
It became clear that valid trials represented homogenous
patient populations with minimal variations in baseline
risks and outcome frequencies. Also, most antiemetic in-
terventions were tested in one or two large multicentre
studies with similar control event rates. As estimates of
the clinical relevance of the antiemetic efficacy of the
treatments, we, therefore, calculated absolute risk reduc-
tions compared with placebo. We also calculated the re-
ciprocal of the absolute risk reduction, the number-
needed-to-treat [11], with 95% confidence interval [12].
Dose-responsiveness was tested for as with previous
similar analyses [8,13], taking into account criteria of
both statistical significance and clinical relevance of dif-
ferences in efficacy between doses. Since control event
rates were very similar in these trials, we were using the
absolute risk reduction (and the number-needed-to-
treat) to test for dose-responsiveness. For homogeneous
subgroups, absolute risk reductions (numbers-needed-
to-treat) were graphically plotted as recently suggested
[14]. A consistent increase in the absolute risk reduction
(a decrease in the number-needed-to-treat) with increas-
ing doses was interpreted as weak evidence of dose-re-
sponsiveness. A statistically significant difference
between two doses, and thus strong evidence of dose-re-
sponsiveness, was assumed when the 95% confidence in-
tervals of the absolute risk reductions (numbers-needed-
to-treat) of these two doses did not overlap, or when the
higher dose was significantly different from control and
the lower dose was not. According to a pre-hoc decision
in the clinical setting of PONV [15], a change of the abso-
lute risk reduction by • 20% was regarded as a clinically
relevant degree of change in antiemetic efficacy. For in-
stance, a decrease of the number-needed-to-treat from 5
to 4 compared with placebo to prevent further vomiting
in a vomiting patient by increasing the dose would be re-
garded as a worthwhile improvement. This would then
justify an increase of the dose [8,13].
Results
Included and excluded articles
We screened 55 reports; 34 of those were potentially rel-
evant for the purpose of this study (Figure 1). Nine had to
be subsequently excluded. Data of one large sponsored
multicentre trial on ondansetron (500 patients) [16]
were published in two further full reports [17,18], and
data of one large sponsored multicentre trial on dolaset-
ron (620 patients) [19] were published in one subse-
quent full report [20]; the original reports only were
considered by us [16,19]. In two trials, treatment alloca-
tion was not randomised; one tested ondansetron [21],
the other pepermint oil [22]. In two trials, patients re-
ceived both prophylactic and therapeutic antiemetic in-
terventions, and efficacy data could not been separated;
one trial tested droperidol and metoclopramide [23], the
other droperidol, metoclopramide, and domperidone
[24]. One trial did not report on efficacy data which were
relevant for the purpose of this analysis [25]. Finally, one
report was on patients with nausea and vomiting due to
oesophageal and gastric disorders [26].
Twenty-five trials fulfilled our inclusion criteria. One on
domperidone was published in 1980 [27], all others were
published after 1990; 11 trials (44%) were published
since 1997. One report was in German [28] all others
were in English. Three trials were in children [29–31], all
others were in adults. In the 17 trials, which reported on
the number of patients who were followed up before ran-
domisation, 12,107 patients were followed up and 3,572
of those vomited or felt nauseous before treatment (aver-
age 30%, range 9% [32] to 63% [33]). We contacted the
main authors of two trials to clarify inconsistencies in the
reporting of late success data [34,35]. One author only
responded to our enquiry [34]; these data were included
in our analyses.
Active controlled trials
In seven randomised trials (1,267 patients)
[28,29,32,36–39], eleven different experimental inter-
ventions were tested without a placebo group (Table 1).
One antiemetic intervention was tested in three trials,
five in two each, and five in one each. Because of the large
Figure 1
Flowchart of retrieved and analysed reports.
Retrieved reports (n=34)
Included trials (n=25)
Active controlled trials (n=7) Placebo controlled trials (n=18)
Duplicate (n=3)
Not randomised (n=2)
Prevention and therapy (n=2)
Inadequate endpoint (n=1)
Not postoperative nausea and vomiting (n=1)BMC Anesthesiology 2001, 1:2 http://www.biomedcentral.com/1471-2253/1/2
variety in different experimental interventions and the
inconsistency in control interventions, these data were
not further analysed.
Placebo controlled trials
In 18 trials (3,809 patients), there was an inactive con-
trol group [16,17,19,27,30,31,33–35,40–48] (Table 2).
Most trials reported separately on anti-nausea and anti-
vomiting data. Three trials also reported on combined
nausea and vomiting data [33–35], and two (one tested
ondansetron and metoclopramide [45], and one tested
domperidone [27]) reported only on combined data.
Combined data were not further analysed.
Eleven trials (61% of all placebo-controlled trials) tested
four 5-HT3receptor antagonists (dolasetron, graniset-
ron, ondansetron, or tropisetron) in 3,427 patients (90%
of all patients in placebo-controlled trials). Average trial
size was 312 patients (range, 36 to 620). Median validity
score was 3 (range, 2 to 5). Most data came from multi-
centre dose-finding studies that were sponsored by the
manufacturers of the respective 5-HT3 receptor antago-
nists.
Three trials tested propofol [35,46,47], and one each mi-
dazolam [48], a NK1 antagonist (GR205171) [33], dom-
peridone [27], and isopropyl alcohol vapor [31] in 382
patients. In those trials, average size was 55 patients
(range, 20 to 100). This was significantly different from
the trials on 5-HT3 receptor antagonists (p = 0.002). Me-
dian validity score was 2 (range, 2 to 4). This was not dif-
ferent from trials on 5-HT3 receptor antagonists (p =
0.126). Two trials were sponsored [33,46].
5-HT3 receptor antagonists
Granisetron 0.1 mg, 1 mg, and 3 mg (386 patients re-
ceived granisetron) and tropisetron 0.5 mg, 2 mg, and 5
mg (237) were tested in one multicentre trial each
[34,41]. Dolasetron 12.5, 25 mg, 50 mg, and 100 mg was
tested in two multicentre trials (765) [19,40]. Data on
ondansetron came from seven trials. Three doses, 1 mg,
4 mg, and 8 mg were tested in 839 adults in two multi-
centre [16,17] and four single centre trials [42–45], and
0.1 mg and 16 mg were tested in 60 adults in one trial
[43]. Finally, 0.1 mg/kg was tested in 192 children in one
trial [30]; this was the only paediatric trial that tested a
setron.
Graphical display suggested similar anti-vomiting effica-
cy with all 5-HT3receptor antagonists, and little evidence
of dose-responsiveness (Table 3, Figure 2). For early suc-
cess, relative risk point estimates were between 1.6 and
2.2, and numbers-needed-to-treat point estimates were
between 3.0 and 4.7. According to our predefined crite-
ria, there was some evidence of dose-responsiveness
with ondansetron; the lowest dose tested, 0.1 mg, was no
different from placebo, and all higher doses were signifi-
cantly more efficacious than placebo. With the main
fixed doses (1 mg, 4 mg, and 8 mg), however, there was
no clinically relevant dose-response; the number-need-
Table 1: Active-controlled trials
Ref Validity score Comparison Surgery Sponsorship
random blinding dropouts (number of patients in brackets)
[28] 1/1/0 1) Ondansetron 8 mg iv (50) 
2) Droperidol 1.25 mg iv (50)
Not reported
[29] 2/2/1 1) Ondansetron 0.1 mg/kg iv (16) 
2) Droperidol 20 µg/kg iv (13)
Extraabdominal
[32] 2/2/0 1) Droperidol 1.25 mg iv (27) 
2) Metoclopramide 10 mg iv (25) 
3) Propofol 10 mg iv (26)
Mixed
[36] 1/1/0 1) Ondansetron 4 mg iv (380) 
2) Metoclopramide 10 mg iv (366)
Not reported Glaxo
[37] 1/1/0 1) Droperidol 20 µg/kg iv (40) 
2) Granisetron 40 µg/kg iv (40) 
3) Metoclopramide 0.2 mg/kg iv (40)
Laparoscopic 
cholecystectomy
[38] 1/1/0 1) Droperidol 20 µg/kg iv (40) 
2) Granisetron 40 µg/kg iv (40) 
3) Metoclopramide 0.2 mg/kg iv (40)
Major 
gynecological
[39] 1/1/1 1) Alizapride 100 mg iv (24) 
2) Droperidol 1 mg iv (25) 
3) Ondansetron 8 mg iv (25)
Gynecological GlaxoBMC Anesthesiology 2001, 1:2 http://www.biomedcentral.com/1471-2253/1/2
Table 2: Placebo-controlled trials
Ref Validity
score
Comparison Surgery Early success Late success Sponsorship
absence of absence of
random 
blinding 
dropouts
(number of patients in 
brackets)
time point nausea vomiting time point nausea vomiting
Dolasetron
[40] 1/1/0 1) Dolasetron 12.5 mg iv (66) 
2) Dolasetron 25 mg iv (65) 
3) Dolasetron 50 mg iv (67) 
4) Dolasetron 100 mg iv (68) 
5) Placebo iv (71)
Mixed no data 24 h no data 16/66 
18/65 
25/67 
17/68 
8/71
Hoechst 
Marion 
Russel
[19] 2/1/0 1) Dolasetron 12.5 mg iv (130) 
2) Dolasetron 25 mg iv (119) 
3) Dolasetron 50 mg iv (124) 
4) Dolasetron 100 mg iv (126) 
5) Placebo iv (121)
Mixed 2 h no data 72/130 
60/119 
60/124 
64/126 
33/121
24 h no data 46/130 
33/119 
36/124 
37/126 
13/121
Hoechst 
Marion 
Russel
Granisetron
[41] 2/1/1 1) Granisetron 0.1 mg iv (128) 
2) Granisetron 1 mg iv (133) 
3) Granisetron 3 mg iv (125) 
4) Placebo iv (133)
Mixed 6 h 51/128 
54/133 
53/125 
22/133
68/128 
77/133 
75/125 
35/133
24 h 34/128 
40/133 
46/125 
17/133
49/128 
61/133 
61/125 
26/133
Tropisetron
[34] 1/2/0 1) Tropisetron 0.5 mg iv (77) 
2) Tropisetron 2 mg iv (80) 
3) Tropisetron 5 mg iv (80) 
4) Placebo iv (77)
Mixed 4 h 45/77 
45/80 
45/80 
35/77
54/77 
61/80 
59/80 
35/77
24 h 33/77 
36/80 
37/80 
26/77
40/77 
46/80 
48/80 
22/77
Sandoz
Ondansetron
[42] 2/2/0 1) Ondansetron 8 mg iv (35) 
2) Placebo iv (36)
Laparoscopy 2 h no data 17/35 
3/36
no data Glaxo
[17] 1/1/1 1) Ondansetron 1 mg iv (112) 
2) Ondansetron 4 mg iv (112) 
3) Ondansetron 8 mg iv (104) 
4) Placebo iv (108)
Not
specified
no data 24 h no data 45/112 
49/112 
43/104 
28/108
Glaxo
[16] 1/1/0 1) Ondansetron 1 mg iv (130) 
2) Ondansetron 4 mg iv (119) 
3) Ondansetron 8 mg iv (122) 
4) Placebo iv (129)
Mixed 2 h no data 74/130 
73/119 
70/122 
39/129
24 h no data 53/130 
56/119 
57/122 
19/129
Glaxo
[30] 2/2/1 1) Ondansetron 0.1 mg/kg iv 
(192) 
2) Placebo iv (183)
Paediatric 2 h no data 150/192
 
63/183
24 h no data 98/186
 
30/179
Glaxo
[44] 2/1/0 1) Ondansetron 8 mg iv (18) 
2) Placebo iv (18)
Mixed 4 h 14/18 
5/18
17/18 
17/18
no data Glaxo
[45] 1/1/1 1) Ondansetron 4 mg iv (58) 
2) Metoclopramide 10 mg iv 
(57) 
3) Placebo iv (60)
Gynaecologic 
laparoscopy
0.5 h Only combined 
nausea+vomiting 
data
48 h Only combined 
nausea+vomiting 
dataBMC Anesthesiology 2001, 1:2 http://www.biomedcentral.com/1471-2253/1/2
ed-to-treat for late anti-vomiting efficacy decreased from
4.8 to 4.1 (i.e. an improvement by 15%). Best anti-vomit-
ing efficacy was with granisetron, and there was some ev-
idence of a clinically relevant dose-response. With the
lowest dose tested (0.1 mg), the number-needed-to-treat
for early success was 3.7. This number decreased to 3.2
(i.e. an improvement by 14%) when the dose was in-
creased by a factor of 10 (to 1 mg). When the dose was
further increased by a factor of 30 (to 3 mg), the number-
needed-to-treat decreased to 3.0 (i.e. an improvement by
23%). For late success, the improvement was 11% and
36%, when the dose was increased to 1 mg and 3 mg, re-
spectively. There was also some evidence of a clinically
relevant dose-response for late anti-vomiting efficacy
with tropisetron. With 0.5 mg, the number-needed-to-
treat to prevent further vomiting for 24 hours was 4.3.
When the dose was increased fourfold, the number-
needed-to-treat decreased to 3.5 (i.e. an improvement by
18%). When the dose was increased tenfold, the number-
needed-to-treat decreased to 3.2 (i.e. an improvement by
26%).
Three trials only reported on anti-nausea efficacy; two
multicentre trials on granisetron [41] and tropisetron
[34], respectively, and one small trial on ondansetron
[44] (Table 2). Anti-nausea efficacy was consistently less
[43] 2/2/0 1) Ondansetron 0.1 mg iv (32) 
2) Ondansetron 4 mg iv (29) 
3) Ondansetron 16 mg iv (28) 
4) Placebo iv (32)
Mixed 6 h no data 7/32 
12/29 
15/28 
5/32
24 h no data 5/32 
11/29 
14/28 
5/32
Glaxo
Propofol
[35] 1/2/0 1) Propofol 20 mg iv (24) 
2) Propofol 40 mg iv (22) 
3) Intralipid iv (23)
Day case 2 h no data 21/24 
17/22 
13/23
no data
[46] 1/1/0 1) Propofol 3 mg iv (12) 
2) Propofol 9 mg iv (12) 
3) Propofol 27 mg iv (12) 
4) Intralipid iv (12)
Gynecologic 
laparoscopy
1.5 h 4/12 
3/12 
3/12 
3/12
10/12 
11/12 
7/12 
10/12
no data ICI Pharma-
ceuticals
[47] 2/1/0 1) Propofol 0.2 mg/kg iv (35) 
2) Intralipid (35)
Adenectomy 
Tonsillectomy
1 h no data 34/35 
30/35
24 h no data 13/35 
20/35
Others
[48] 2/2/0 1) Midazolam 1 mg iv + 1 mg/h 
(10) 
2) Placebo iv (10)
Any surgery 9 h no data 9/10
 
3/10
no data
[33] 1/1/0 1) GR205171 25 mg iv (18) 
2) Placebo iv (18)
Hysterectomy 2 h 10/18 
4/18
14/18 
5/18
24 h Only combined 
nausea+vomiting 
data
Glaxo
[27] 1/1/0 1) Domperidone 10 mg iv (52) 
2) Placebo iv (48)
Mixed 6 h Only combined 
nausea+vomiting 
data
no data
[31] 2/0/0 1) Isopropyl alcohol vapor 
nasal (20) 
2) Saline nasal (19)
Paediatric 1 h 18/20 
8/19
7/20
 
2/19
no data
All trials are in adults, except "paediatric"
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pronounced, compared with the anti-vomiting efficacy
(Table 3, Figure 2). For tropisetron, none of the doses
tested achieved a statistically significant anti-nausea ef-
fect, neither early nor late.
The most frequently reported adverse effect with 5-HT3
receptor antagonists was headache (Table 4). There was
some evidence of dose-responsiveness, although for
none of the dose groups tested (i.e. low, medium or high)
the result was statistically significant. With the lowest
doses, the risk of headache was decreased compared with
placebo. With the medium doses, there was equivalence.
With the highest doses tested, the risk of headache was
increased compared with placebo.
Propofol
Six different regimens of propofol were tested in three
trials, each in a limited number of patients [35,46,47]
(Table 2). Results were inconsistent. There was a lack of
evidence of any dose-effect, or increased efficacy in par-
ticular groups of patients. When the data were com-
bined, there was no evidence of a significant anti-
vomiting effect (Table 3). One trial only tested early anti-
nausea efficacy [46]; the effect was not statistically sig-
nificant. In two trials, increased sedation with propofol
was reported [35,46]. In one trial, one of 22 patients re-
ceiving propofol 40 mg had an episode of apnoea [35].
Others
One trial each tested a NK1-receptor antagonist [33], mi-
dazolam [48], domperidone [27], nasal isopropyl alcohol
[31], and metoclopramide [45] (Tables 2 and 3). Trials
were on a limited number of patients, or reported com-
bined nausea and vomiting success rates only.
None of the trials reported on the number of outpatients
who needed to be admitted due to intractable PONV.
Discussion
There are three main results of this systematic review.
First, 5-HT3receptor antagonists are efficacious to some
extent in preventing further vomiting in a patient who is
vomiting after surgery; they show less efficacy in pre-
venting further nausea in a nauseated patient. Second,
over wide ranges of doses there is weak evidence only of
dose-responsiveness with these drugs. Third, although
classic antiemetics (for instance, droperidol or metoclo-
pramide) have been widely used for decades, there is a
lack of evidence on their therapeutic efficacy in the post-
operative period.
The 5-HT3 receptor antagonists were the most frequent-
ly tested drugs. For all of them at least one large and well
designed multicentre trial could be retrieved. Thus, for
this class of antiemetics, treatment recommendations
can be based on strong evidence. There were, however,
some methodological problems with these trials. For in-
stance, some of them were published more than once
[17,18,20]. Also, there were no reports on direct compar-
isons of 5-HT3 receptor antagonists. Our analyses had to
rely on indirect comparisons from placebo-controlled
trials. Finally, for most of these trials, reporting of effica-
cy data was incomplete. It is important to distinguish be-
tween anti-vomiting and anti-nausea efficacy since
nausea is not a little vomiting [49]. An antiemetic may
well stop further vomiting in a vomiting patient but leave
the patient nauseous. For both granisetron and tropiset-
ron, there was consistent evidence that the anti-nausea
effect was less pronounced than the anti-vomiting effect.
For the other setrons no nausea data were reported. This
relative lack of anti-nausea efficacy of 5-HT3 receptor an-
tagonists has been well known from previous analyses on
prophylactic ondansetron in the surgical setting [13],
and on the antiemetic efficacy of 5-HT3 receptor antago-
nists in patients undergoing radiotherapy [50]. The se-
lective reporting of anti-vomiting efficacy data in the
majority of these trials may lead to a biased perception of
the antiemetic efficacy of 5-HT3 receptor antagonists.
To know about dose-responsiveness is important for two
reasons. First, when larger doses are not much more ef-
ficacious than smaller doses, the smaller doses are likely
to be more cost-effective. Second, smaller doses may be
Figure 2
Prevention of further postoperative nausea and vomiting
with 5-HT3 receptor antagonists. Symbols are absolute risk
reductions (ARR) or numbers-needed-to-treat (NNT),
respectively, with 95% confidence intervals. Symbol sizes are
proportional to the number of analysed patients. White cir-
cles: vomiting; grey squares: nausea. ∞  = infinity (ARR = 0).
All data are from adults.
Dolasetron 12.5 mg
Dolasetron 25 mg
Dolasetron 50 mg
Dolasetron 100 mg
Granisetron 0.1 mg
Granisetron 1 mg
Granisetron 3 mg
Tropisetron 0.5 mg
Tropisetron 2 mg
Tropisetron 5 mg
Ondansetron 0.1 mg
Ondansetron 1 mg
Ondansetron 4 mg
Ondansetron 8 mg
Ondansetron 16 mg
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NNT
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Table 3: Efficacy data
Early success Late success
Success rate Relative Risk Number 
Needed To 
Treat
Ref Success rate Relative Risk Number 
Needed To 
Treat
Ref
Active Control* (95% confidence
interval)
(95% confi-
dence
interval)
Active Control* (95% confidence
interval)
(95% confidence
interval)
Prevention of further nausea
Granisetron
0.1 mg 40% 17% 2.41 (1.56 to 3.73) 4.3 (3.0 to 7.9) [41] 27% 13% 2.08 (1.22 to 3.53) 7.3 (4.3 to 24) [41]
1 mg 41% 17% 2.45 (1.59 to 3.79) 4.2 (2.9 to 7.4) [41] 30% 13% 2.35 (1.41 to 3.93) 5.8 (3.7 to 13) [41]
3 mg 42% 17% 2.56 (1.66 to 3.95) 3.9 (2.7 to 6.6) [41] 37% 13% 2.88 (1.75 to 4.75) 4.2 (2.9 to 7.2) [41]
Tropisetron
0.5 mg 58% 45% 1.29 (0.94 to 1.75) 7.7 (3.5 to -38) [34] 43% 34% 1.27 (0.85 to 1.90) 11 (4.1 to -16) [34]
2 mg 56% 45% 1.24 (0.91 to 1.69) 9.3 (3.8 to -21) [34] 45% 34% 1.33 (0.90 to 1.98) 8.9 (3.8 to -25) [34]
5 mg 56% 45% 1.24 (0.91 to 1.69) 9.3 (3.8 to -21) [34] 46% 34% 1.37 (0.93 to 2.03) 8.0 (3.6 to -37) [34]
Ondansetron
8 mg 78% 28% 2.80 (1.28 to 6.14) 2.0 (1.3 to 4.6) [44] no data
Propofol
any dose 36% 25% 1.44 (0.49 to 4.22) 9.0 (2.5 to -5.6) [46] no data
Other drugs
GR205171 
25 mg
56% 22% 2.50 (0.96 to 6.52) 3.0 (1.6 to 29) [33] no data
Isopropyl 
alcohol
90% 42% 2.14 (1.24 to 3.69) 2.1 (1.4 to 4.5) [31] no data
Prevention of further vomiting
Dolasetron
12.5 mg 55% 27% 2.03 (1.46 to 2.82) 3.6 (2.5 to 6.1) [19] 32% 11% 2.88 (1.83 to 4.54) 4.8 (3.5 to 7.8) [19][40]
25 mg 50% 27% 1.85 (1.31 to 2.60) 4.3 (2.8 to 9.0) [19] 28% 11% 2.54 (1.59 to 4.04) 6.0 (4.1 to 11) [19][40]
50 mg 48% 27% 1.77 (1.26 to 2.50) 4.7 (3.0 to 11) [19] 32% 11% 2.93 (1.86 to 4.61) 4.8 (3.5 to 7.7) [19][40]
100 mg 51% 27% 1.86 (1.33 to 2.61) 4.3 (2.8 to 8.5) [19] 28% 11% 2.54 (1.60 to 4.04) 5.9 (4.1 to 11) [19][40]
Granisetron
0.1 mg 53% 26% 2.02 (1.45 to 2.80) 3.7 (2.6 to 6.5) [41] 38% 20% 1.96 (1.30 to 2.95) 5.3 (3.4 to 13) [41]
1 mg 58% 26% 2.20 (1.60 to 3.03) 3.2 (2.3 to 4.9) [41] 46% 20% 2.35 (1.59 to 3.47) 3.8 (2.7 to 6.5) [41]
3 mg 60% 26% 2.28 (1.66 to 3.13) 3.0 (2.2 to 4.5) [41] 49% 20% 2.50 (1.69 to 3.68) 3.4 (2.5 to 5.5) [41]
Tropisetron
0.5 mg 70% 45% 1.54 (1.16 to 2.05) 4.1 (2.5 to 10) [34] 52% 29% 1.82 (1.20 to 2.75) 4.3 (2.6 to 12) [34]
2 mg 76% 45% 1.68 (1.28 to 2.21) 3.2 (2.2 to 6.1) [34] 58% 29% 2.01 (1.35 to 3.00) 3.5 (2.3 to 7.1) [34]
5 mg 74% 45% 1.62 (1.23 to 2.14) 3.5 (2.3 to 7.4) [34] 60% 29% 2.10 (1.41 to 3.12) 3.2 (2.2 to 6.0) [34]
Ondansetron
0.1 mg 22% 16% 1.40 (0.50 to 3.95) 16 (4.0 to -7.8) [43] 16% 16% 1.00 (0.32 to 3.12) ∞  (5.6 to -5.6) [43]
1 mg 57% 30% 1.88 (1.39 to 2.55) 3.7 (2.6 to 6.6) [16] 40% 20% 2.04 (1.51 to 2.75) 4.8 (3.5 to 7.9) [16][17]
4 mg 57% 27% 2.10 (1.58 to 2.79) 3.3 (2.5 to 5.1) [16][43] 45% 19% 2.29 (1.73 to 3.02) 4.0 (3.0 to 5.7) [16][17]
[43]
8 mg 59% 32% 1.84 (1.45 to 2.35) 3.7 (2.7 to 5.8) [16][42]
[44]
44% 20% 2.23 (1.66 to 3.00) 4.1 (3.1 to 6.2) [16][17]
16 mg 54% 16% 3.43 (1.43 to 8.23) 2.6 (1.7 to 6.4) [43] 50% 16% 3.20 (1.32 to 7.76) 2.9 (1.8 to 8.3) [43]
0.1 mg/kg 78% 34% 2.27 (1.83 to 2.81) 2.3 (1.9 to 2.9) [30] 53% 17% 3.14 (2.21 to 4.48) 2.8 (2.2 to 3.7) [30]
Propofol
any dose 85% 76% 1.18 (1.01 to 1.37) 10 (4.6 to -47) [35][46]
[47]
53% 57% 0.88 (0.64 to 1.22) -26 (7.7 to -4.9) [35][47]
Other drugs
GR205171 
25 mg
78% 28% 2.80 (1.28 to 6.14) 2.0 (1.3 to 4.6) [33] no data
Isopropyl 
alcohol
35% 11% 3.33 (0.79 to 14.0) 4.1 (2 to -174) [31] no data
Midazolam 90% 30% 3.00 (1.14 to 7.91) 1.7 (1.1 to 3.8) [48] no data
*control = placebo, except in propofol trials where control = intralipid; ∞  = infinity (absolute risk reduction = 0)BMC Anesthesiology 2001, 1:2 http://www.biomedcentral.com/1471-2253/1/2
less harmful. As in previous analyses, we have chosen a
combined approach to test for dose-responsiveness, tak-
ing into account graphical display, an estimate of the sta-
tistical significance of the difference between doses, and
an estimate of the clinical relevance of such a difference.
Our aim was to facilitate decision-making using a prag-
matic and robust method which is clinically applicable.
Thus, the major question whether or not to increase the
dose of an antiemetic was mainly based on the clinical
relevance of any improvement in efficacy. Therefore, and
since these trials represented clinically homogenous data
and very similar control event rates, we were using the
absolute risk reduction and the number-needed-to-treat,
respectively, to test for dose-responsiveness. For none of
the setrons there was strong evidence of dose-respon-
siveness. For ondansetron there was some weak evi-
dence; however, the subthreshold dose (0.1 mg) and the
dose that was 160 times higher (16 mg) were tested in a
very limited number of patients only.
The lack of a clear dose-response with these 5-HT3 re-
ceptor antagonists in the surgical setting is surprising for
two reasons. First, wide dose ranges were tested. For do-
lasetron, the doses differed by a factor of 8, for tropiset-
ron by 10, and for granisetron even by 30. This means
that for granisetron, for instance, 30 times more drug
costs must be spent to safe an additional 10% of vomiting
patients from further vomiting (Table 3). Second, for on-
dansetron there is evidence from systematic review that
the optimal dose to prevent PONV is likely to be 8 mg
[13]. For therapeutic purposes, however, 1 mg seems to
be as efficacious as higher doses (Table 3, Figure 2). This
is interesting both from a pharmacologic and an eco-
nomic point of view. Pharmacologically, these data sug-
gest that minimal amounts of ondansetron are needed to
block 5-HT3 receptors in a vomiting patient, but that
much higher doses are needed to block these receptors
prophylactically. We do not know if this is a kinetic or a
dynamic phenomenon, but we may assume that it ap-
plies to all setrons. Economically, this observation is in-
teresting since these drugs are relatively expensive. It
may make a difference if all surgical patients (including
those who actually will not need an antiemetic) receive
prophylactically a high dose of an expensive drug, or if
only those who are suffering from PONV symptoms will
be treated with a small (but effective) dose of the same
drug. The pragmatic clinical message is that with all
these tested 5-HT3 receptor antagonists, minimal doses
may be used to treat established PONV symptoms, while
much higher doses are needed to try to prevent these
symptoms. Obviously, with the treatment strategy, a pa-
tient will have to vomit first or suffer some degree of nau-
sea before she gets a rescue medication.
Headache is a well known adverse effect of 5-HT3 recep-
tor antagonists [13,50]. With the highest doses of all four
5-HT3 receptor antagonists, the risk of headache com-
pared with placebo was increased (although not statisti-
cally significant). This may be regarded as a further
argument to use minimal effective doses of these drugs.
None of the other well known adverse effects of 5-HT3 re-
ceptor antagonists, elevated liver enzymes or constipa-
tion [13,50], have been reported in more than one trial.
A final issue relates to the lack of valid data on the thera-
peutic efficacy of the classic antiemetics in the postoper-
ative period. This is problematic since many of these old
antiemetics have been used for decades, and they are still
widely used in daily clinical practice. However, unless
their relative efficacy is established, there cannot be evi-
dence-based treatment recommendations for PONV.
There is a plethora of randomised clinical trials on the
prevention of PONV symptoms and a paucity of thera-
peutic trials, and there may be several reasons for this
Table 4: Risk of headache with 5-HT3 receptor antagonists
Number with
5-HT3 receptor antagonist 
(mg)
Event rate Relative risk References
headache/Total number
Dose Dolas-
etron
Grani-
setron
Tropi-
setron
Ondans
etron
Active Placebo Active Placebo 95% confidence
interval
Low: 12.5 0.1 0.5 1 7.7% 10.4% 41/531 55/531 0.75 (0.51 to 1.10) [16] [19] [34] [40] 
[41] 
Medium: 25, 50 1 2 4 9.3% 9.3% 71/765 55/591 1.09 (0.78 to 1.52) [16] [19] [34] [40] 
[41][45]
High: 100 3 5 8 13.3% 9.9% 74/556 56/567 1.36 (0.98 to 1.88) [16] [19] [34] [40] 
[41][42]
Doses have been grouped arbitrarily into "low", "medium", and "high"; these groups do not represent equipotent doses.BMC Anesthesiology 2001, 1:2 http://www.biomedcentral.com/1471-2253/1/2
discrepancy. Therapeutic trials are logistically more dif-
ficult to perform. If the baseline risk of 30% vomiting
and nauseous postoperative patients is about right, then
of 1,000 patients who have given their informed consent
to take part in a therapeutic trial, 300 may eventually
suffer from PONV symptoms. Only these may then be
randomised and treated, and need to be followed-up for
24 hours. Trialists may prefer to give a drug to all pa-
tients prophylactically, and then see what's happening.
Also, manufacturers may have more commercial interest
in prophylaxis strategies than in treatment strategies,
since then all patients will receive the drug and not only
those who actually need it. Most valid data came from
large multicentre trials that have been designed and
sponsored by the manufacturers of the modern 5-HT3
receptor antagonists. Most of these trials were laudable
examples of placebo-controlled dose-finding studies.
However, none of them compared two 5-HT3 receptor
antagonists. And one only compared a 5-HT3 receptor
antagonist with a classic antiemetic [36]. In that trial,
ondansetron 4 mg was superior to metoclopramide 10
mg. Metoclopramide 10 mg, however, is not antiemetic
[51].
It seems that manufacturers of old classic antiemetics
are not interested in testing their compounds in well de-
signed large trials; these drugs are widely used anyway
despite the lack of evidence-based high-quality data. For
none of these classic antiemetics, a dose-response has
been established, and for none the optimal dose to treat
established PONV is known. Manufacturers of the new
compounds have produced high-quality data. However,
they are not keen to compare their drugs with other new
active comparators, or with effective regimens of old an-
tiemetics. Also, in these trials, anti-nausea data are often
underreported. This may lead to a false impression of an-
tiemetic efficacy.
Conclusions
In postoperative patients who are suffering from nausea
or vomiting, 5-HT3 receptor antagonist have some effect
on vomiting and less so on nausea. Minimal effective
doses should be used since these are as effective as much
higher doses. There is a lack of valid data for the classic
antiemetics. Evidence-based treatment strategies that
take into account all possible antiemetic interventions
have not yet been established [49]. If anaesthesiologists
do not want to rely exclusively on drugs that are expen-
sive and of limited anti-nausea efficacy they need to de-
sign valid trials with older classic antiemetics. Future
trials should be randomised, properly double-blind, and
placebo-controlled. They should report on both short (up
to 6 hours after treatment) and long (to 24 hours) obser-
vation periods, although it would be useful to also report
on the delay until the antiemetic treatment shows effica-
cy. Nausea and vomiting should be separately reported,
and adverse drug reactions need to be documented.
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